AZD3463

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (6)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–6 of 6 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ROS1 Fusion + ROS1 G2032R1
AZD3463 + Brigatinib

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

ALK F1174L + ALK Fusion1
AZD3463	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	2	submitted	EID12682 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK F1174L co-mutation, demonstrated similar sensitivity to AZD3463 treatment (IC50: 15… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic

ALK G1269A + ALK Fusion1
AZD3463	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	2	submitted	EID12680 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK G1269A co-mutation, demonstrated similar sensitivity to AZD3463 treatment (IC50: 11… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic

ALK I1171S + ALK Fusion1
AZD3463	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	2	submitted	EID12679 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK I1171S co-mutation, demonstrated increased resistance to AZD3463 treatment (IC50: 3… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic

ALK R1192P + ALK Fusion1
AZD3463	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	2	submitted	EID12681 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK R1192P co-mutation, demonstrated similar sensitivity to AZD3463 treatment (IC50: 10… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic

ALK F1174L1
AZD3463	Neuroblastoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID1327 The SH-SY5Y neuroblastoma cell line containing the F1174L ALK mutation was found to undergo cell death when treated with the ALK/IGF1R inhibitor AZD3463. These cells were more sensitive than other neu… (full text at CIViC) PMID 26786851 · Wang et al., 2016 · Open in CIViC	civic